GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Beta

Cantargia AB (OSTO:CANTA) Beta : N/A (As of Jun. 07, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-07), Cantargia AB's Beta is Not available.


Cantargia AB Beta Historical Data

The historical data trend for Cantargia AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Beta Chart

Cantargia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 1.27 0.35 0.97 1.29

Cantargia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.53 1.20 1.29 1.88

Competitive Comparison of Cantargia AB's Beta

For the Biotechnology subindustry, Cantargia AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Beta distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Beta falls into.



Cantargia AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Cantargia AB  (OSTO:CANTA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cantargia AB Beta Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB (OSTO:CANTA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB (OSTO:CANTA) Headlines

No Headlines